3 AI Healthcare Stocks Backed By Real Clinical Use And Fast Revenue Growth

Artificial intelligence in healthcare sits at the intersection of two powerful forces investors are watching closely right now: pressure on costs and demand for better outcomes. With inflation data mixed across regions and central banks weighing their next moves, many investors are looking for themes driven less by broad cycles and more by real-world productivity and efficiency gains. The Transformative AI Healthcare Stocks screener focuses on companies using AI to improve diagnostics, treatment decisions, operations and research. This article highlights three stocks from that screener to help you explore how this theme might fit in a diversified portfolio.

Eastwood Bio-Medical Canada (TSXV:EBM)

Overview: Eastwood Bio-Medical Canada markets and distributes Eleotin branded natural health products that target metabolic disorders such as blood glucose issues, hypertension and obesity, along with a range of supplements aimed at cardiovascular, bone and general wellness across Canada, the United States and Asia. The company is also working with BioNexus to apply artificial intelligence to large herbal prescription datasets to identify potential natural drug and functional food candidates.

Operations: Eastwood Bio-Medical Canada currently generates about CA$0.79 million in revenue from the distribution of Eleotin and related products, with most sales coming from Asia and smaller contributions from Canada and the U.S.

Market Cap: CA$68.89 million

Eastwood Bio-Medical Canada sits at the junction of traditional herbal remedies and AI driven product discovery, which gives it a differentiated angle within healthcare AI. Earnings have grown around 9% annually over the past 5 years and recent Q2 and half year figures show revenue and losses moving in a more favorable direction. However, the company remains small, is currently unprofitable, operates with negative equity and has a high reliance on external borrowing. The new AI platform project with BioNexus, starting with roughly 250,000 blood glucose related prescriptions, could be important for future product development. Combined with an experienced, largely independent board and a highly volatile share price, Eastwood Bio-Medical Canada may particularly suit investors who fully understand the balance between its early stage profile and its funding risks.

Eastwood Bio-Medical Canada blends traditional herbal IP with AI driven discovery, yet its early stage balance sheet and funding needs are easy to underestimate. Review the full Eastwood Bio-Medical Canada financial health report for more details.

Profound Medical (TSX:PRN)

Overview: Profound Medical develops and markets AI powered, MRI guided systems that let doctors ablate diseased tissue without surgical incisions. Its key products are the TULSA PRO platform for targeted prostate treatment and the Sonalleve system for certain benign tumors and palliative pain. The company sells these technologies to hospitals and clinics in Canada, the U.S., Germany, China and Finland.

Operations: Profound Medical generates about US$18.8 million in revenue, almost entirely from its medical technology segment, with roughly US$12.3 million from the U.S. and US$5.8 million from Canada.

Market Cap: CA$369.19 million

Profound Medical provides direct exposure to AI enabled, MRI guided procedures that aim to treat prostate disease and other conditions with less invasive approaches. Recent Q1 2026 results show revenue of US$5.34 million and a reduced net loss of US$7.05 million. Available forecasts indicate expectations for rapid revenue and earnings expansion and the possibility of a move to profitability within three years if those expectations are realized. At the same time, the stock has recently lagged the broader Canadian market, the P/S multiple sits well above industry averages and shareholders have experienced dilution alongside high CEO pay, so investors need to weigh potential growth opportunities against valuation, funding and governance pressures.

Profound Medical’s push toward AI guided procedures with a higher than average P/S multiple raises a clear question: is the growth story strong enough to justify today’s pricing, or does the analyst forecasts for Profound Medical reveal something crucial investors are missing?

Perimeter Medical Imaging AI (TSXV:PINK)

Overview: Perimeter Medical Imaging AI develops imaging systems that help surgeons see the edges of cancerous tissue in real time during operations, using optical coherence tomography and artificial intelligence to visualize and assess excised tissue margins, particularly in breast conserving surgery. The company also supports hospitals and cancer centers with an image library and consumable products that fit into existing surgical workflows.

Operations: Perimeter Medical Imaging AI currently generates about US$2.14 million from medical imaging systems in Canada.

Market Cap: CA$49.10 million

Perimeter Medical Imaging AI may appeal if you are looking for AI in healthcare that is tightly linked to real world clinical use, with Claire OCT+AI already FDA approved as an intraoperative breast cancer margin assessment tool and supported by a large image library of more than 2 million breast tissue images. Forecast revenue growth of about 48.1% a year and a share price that sits well below one estimate of fair value are encouraging, but they sit beside ongoing losses, limited current revenue and a heavy reliance on external funding and recent equity and debenture issues. For investors, the core question is whether that funding and recent grants, such as INOVAIT and Mitacs support, will provide sufficient runway for the technology to prove its commercial potential.

Perimeter Medical Imaging AI sits at the crossroads of fast projected growth and real world surgical adoption, yet the market reaction looks cautious. The analyst forecasts for Perimeter Medical Imaging AI could reveal whether that caution is justified or if something important is being overlooked.

The three stocks in this article are just a starting sample, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfaces four more companies with equally compelling AI healthcare narratives that you have not seen yet. Use Simply Wall St to identify and analyze the specific catalysts mentioned here, from diagnostic accuracy and personalized treatments to hospital efficiency and remote care, so you can filter for the highest conviction plays in this theme.

Take Control of Your Investment Journey

If Profound Medical or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Today’s Ideas?

Markets move fast, and the next breakout stories often gain momentum quietly before headlines catch them. Scan these fresh stock ideas while it matters and get in early.

• Spot under the radar value plays before they are widely talked about by checking companies in the 5 high quality undervalued stocks that still sit off most investors’ radar.
• Explore potential AI-related opportunities by focusing on cash generating specialists in the 63 profitable AI stocks that aren't just burning cash that are not just chasing hype or rapidly depleting resources.
• Look for long term compounding potential with founders still at the helm by reviewing the curated 3 top founder-led companies where incentives and ownership stay closely aligned.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com